Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Mantle cell lymphoma (MCL): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Mantle cell lymphoma: the short answer

For mantle cell lymphoma, the US FDA has approved six medicines covered on this page, each for a specific group of patients: Beqalzi, Brukinsa, Jaypirca, Calquence, Tecartus and Breyanzi. Where a medicine is not registered in your country, the treating hospital can ask the national regulator for permission to import it for one named patient. Reserve Meds is a digital health company that helps families and hospitals with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Beqalzi, Brukinsa, Jaypirca, Calquence, Tecartus and Breyanzi.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital; cell and gene therapies at a qualified center.
Price: Quote on request.

What is mantle cell lymphoma?

Mantle cell lymphoma is a less common type of B-cell non-Hodgkin lymphoma. In the United States it accounts for about 5 percent of non-Hodgkin lymphomas, with about 4,000 new cases a year. The median age at diagnosis is about 65, and most cases occur in men.^[1]

It appears in the lymph nodes, spleen and bone marrow, and sometimes in the bowel. Most patients have stage III or IV disease at diagnosis. It usually responds well to treatment but is not curable in most cases, which is why patients often need more than one line of treatment over time.^[1]

Mantle cell lymphoma in the Gulf

We did not find published Gulf-specific figures for mantle cell lymphoma that we could verify, so we do not give any. On 17 October 2026, Beqalzi, the newest medicine on this page, was not found in the SFDA drugs list or the Abu Dhabi Department of Health drug code list. We did not check the other medicines on this page in those registers.^{[2, 3]}

Two of the options, Tecartus and Breyanzi, are CAR-T cell therapies made from each patient's own T cells, so they involve a center that can collect the cells and give the infusion. The tablet medicines can be imported for one named patient where they are not registered.^{[4, 5, 6, 7]}

US FDA-approved medicines for mantle cell lymphoma

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

Beqalzi (sonrotoclax)
FDA-approved for adults with mantle cell lymphoma that has come back or not responded after at least two lines of treatment, including a BTK inhibitor. It is a tablet taken once daily after a 4-week dose ramp-up. Approved under accelerated approval.^{[8, 9]}
US FDA approval: 13 May 2026. Gulf registers: Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked.^{[2, 3]}
Brukinsa (zanubrutinib)
FDA-approved for adults with mantle cell lymphoma who have had at least one prior treatment (accelerated approval). The label also covers other B-cell cancers.^[10]
Current US label version: 21 July 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
Jaypirca (pirtobrutinib)
FDA-approved for adults with mantle cell lymphoma that has come back or not responded after at least two lines of treatment, including a BTK inhibitor (accelerated approval).^[11]
Current US label version: 6 March 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan, Turkey, India, Pakistan
Calquence (acalabrutinib)
FDA-approved for adults with previously untreated mantle cell lymphoma who cannot have an autologous stem cell transplant (with bendamustine and rituximab), and adults with mantle cell lymphoma after at least one prior treatment.^[12]
Current US label version: 19 February 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
Tecartus (brexucabtagene autoleucel)
FDA-approved for adults with mantle cell lymphoma that has come back or not responded to treatment. It is a CAR-T cell therapy made from the patient's own T cells.^[4]
Current US label version: 16 June 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Turkey
Breyanzi (lisocabtagene maraleucel)
FDA-approved for adults with mantle cell lymphoma that has come back or not responded after at least two prior lines of treatment, including a BTK inhibitor. It is a CAR-T cell therapy made from the patient's own T cells.^[5]
Current US label version: 20 February 2026. Gulf registers: Not part of our 17 October 2026 Gulf register check. We confirm the status for your country when you ask.
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan

How families in the Gulf can access these medicines

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[6, 7]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

For Tecartus and Breyanzi. These are made for one patient or given through a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center abroad that can give the treatment. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves the import. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for mantle cell lymphoma

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for mantle cell lymphoma?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Beqalzi, Brukinsa, Jaypirca, Calquence, Tecartus and Breyanzi. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Beqalzi available in Saudi Arabia or the UAE?

Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked. A listing in Abu Dhabi does not show federal UAE status, which we could not verify.

How can a family in the Gulf get Beqalzi?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Is ibrutinib (Imbruvica) still approved for mantle cell lymphoma in the US?

The current US label for Imbruvica, which we checked on 17 October 2026, does not list mantle cell lymphoma. Ask your hematologist about the options on this page instead.

Sources for the last answer: ^[13]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.